IARS1 and breast carcinoma: A more promising approach uses the small-molecule tyrphostin, NT157 to target IRS; this method downregulates IRS protein expression and sensitizes ERα+ breast cancer cells to the mammalian target of rapamycin (mTOR) inhibitor, rapamycin.